Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)

The rising cost of oncological drugs poses a global challenge to patients, insurers, and policy makers, with the leading drugs worldwide by revenue from immune checkpoint inhibitors (ICIs). Despite its cost, ICI is marked as a paradigm shift, offering the potential of a long-term cure. To reduce cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Jia Li, Huang, Yiqing, Sooi, Kenneth, Chan, Zhi Yao, Yong, Wei Peng, Lee, Soo Chin, Goh, Boon Cher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714462/
https://www.ncbi.nlm.nih.gov/pubmed/36465401
http://dx.doi.org/10.3389/fonc.2022.932212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714462/
https://www.ncbi.nlm.nih.gov/pubmed/36465401
http://dx.doi.org/10.3389/fonc.2022.932212

Ejemplares similares